Abstract
Objective
To study the therapeutic effect of combined therapy with Chinese drugs and immuno-suppressors, mainly anti-lymphocyte globulin/anti-thymus globulin (ALG/ATG), for the treatment of severe aplastic anemia (SAA), the efficacy associated factors and adverse effects as well.
Methods
A retrospective analysis was conducted on 65 patients with SAA treated by combined therapy which was supplemented with cyclosporin A, androgen, hematopoietic growth factor, etc.
Results
Of the 57 patients followed-up, 26 (45.6%) were basically cured, 15 (26.3%) remitted, and 8 (14.0%) improved markedly, the total effective rate being 85.9%. By separately comparing with a single item of clinical data, it was shown that the therapeutic effectiveness was correlated, to a certain extent, with age, illness duration, neutrophil count, and bone marrow proliferation in patients before treatment, as well as with infection that occurred in the follow-up period. It was obviously higher in patients with peripheral neutrophil count > 0.5 × 10 109/L (P<0.05). Various degrees of serum sickness-like reactions occurred in the treatment of 36 patients, including fever in 36 (63.2%), skin rash in 8 (14.0%), and musculoskeletal pain in 5 (8.8%).
Conclusions
The therapeutic effect of combined therapy with Chinese drugs and ALG/ATG in treating SAA could be affirmed, showing some superiority as compared with Western medicine alone. The patients’ age, duration of illness, neutrophil count, and bone marrow proliferation before treatment, and degree of infection that occurred could affect the therapeutic efficacy to a certain extent. Adverse reactions resulting from the combined therapy are less, showing the toxicity reducing and effect enhancing action of Chinese drugs.
Similar content being viewed by others
References
He GS, Shao ZH. Current situation of immune inhibitory treatment on aplastic anemia. Chin J Hematol (Chin) 2002;23:611–613.
Chu YL, Hao YS, Bian SK. Clinical study of antithymocyte globulin in the treatment of children aplastic anemia. Chin J Hematol (Chin) 1986;7:198.
Zhang ZN, ed. Norm for diagnosis and efficacy assessment of hematopathy. Beijing: Science Press; 2008:19–23.
Ying XM, Wang YP. Adverse reaction of antithymocyte globulin in the treatment of 28 cases children aplastic anemia. J China Pediatr Blood (Chin) 2000;5:198–201.
Yu F, Tang SQ, Wang JW. Therapeutic effect of antithymocyte/antilymphocyte globulin on severe aplastic anemia and therapy-related complications. Chin J Contemporary Pediatr (Chin) 2006;8:479–481.
Bacigalupo A, Brand R, Oneto R, Oneto R, Bruno B, Socie G, Passweg J, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-The European Group for Blood and Marrow Transplantation Experience. Semin Hematol 2000;37:69–80.
Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000;95:1931–1934.
Rosenfeld S, Follmann D, Nunezo, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003;289:1130–1135.
Shao ZH, Yuan Y. Immune pathogenesis and therapy for aplastic anemia. Chin J Pract Intern Med (Chin) 2006;26:252–255.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by the Key Program of the Governmental Office of Sciences and Technology of Zhejiang Provincial (No. 2006c23039)
Rights and permissions
About this article
Cite this article
Zheng, Br., Shen, Jp., Zhuang, Hf. et al. Treatment of severe aplastic anemia by immunosuppressor anti-lymphocyte globulin/anti-thymus globulin as the chief medicine in combination with Chinese drugs. Chin. J. Integr. Med. 15, 145–148 (2009). https://doi.org/10.1007/s11655-009-0141-9
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-009-0141-9